Loxiglumide

Research use only, not for human use.

Loxiglumide is a cholecystokinin (CCK-1) receptor antagonist.

Loxiglumide is a potent, orally active, and selective CCK-A receptor antagonist which stimulates calorie intake and hunger feelings in humans. Loxiglumide inhibits pancreatic secretion of digestive enzymes, and also blocks CCK-induced gastric secretions and emptying. Intravenous administration of loxiglumide antagonized the CCK-induced reduction of gastric emptying in rats, acceleration of intestinal transport in mice, increase in ileal motility in rabbits, gallbladder contraction in guinea pigs and acceleration of gallbladder emptying in mice.

——

The effects of pancreatic rest by oral administration of CCK-1 receptor antagonist Loxiglumide and pancreas stimulation are investigated via endogenous CCK release induced by po protease inhibitor camostat on the recovery of pancreatic secretory function, and biochemical and histological changes of the pancreas after acute hemorrhagic pancreatitis. Oral administration of CCK-1 receptor antagonist Loxiglumide with a dose of 50 mg/kg body weight inhibits pancreatic exocrine secretion for more than 12 h. Thus, every 12-h administration of Loxiglumide might have completely blocks the effect of endogenously released CCK on the pancreas (pancreatic rest).

CR-1505 | Loxiglumide, brand name: Loxizin.

Others

Other Targets

CCK

——

——

107097-80-3

461.38

C21H30Cl2N2O5

>98% (HPLC)

DMSO : ≥ 150 mg/mL; 325.11 mM

CCCCCN(CCCOC)C(=O)C(CCC(=O)O)NC(=O)c1cc(c(cc1)Cl)Cl

4-(3,4-dichlorobenzamido)-5-((3-methoxypropyl)(pentyl)amino)-5-oxopentanoic acid

(-20℃)

With Ice Pack

≥ 2 years